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Within 2021, Norway intends to complete implementation of HPV DNA-based primary
screening for cervical cancer for women 34–69 years, while continue cytology-based
screening for women 25–33 years. Over the recent years, the incidence of cervical cancer
has increased by 30% among women younger than 40 years. In this subset of women,
nearly 30% were diagnosed with a normal smear, as most recent smear, prior the cancer
diagnosis. This observation demands quality control of normal smears. The aim of this
study was to assess increase in program sensitivity of CIN2+ after follow-up of women with
false negative Pap-smears testing positive for a 3-type (-16, -18, -45) HPV mRNA test in a
cohort design over one screening interval. 521 women, aged 23–39 years, and no prior his-
tory of CIN1+ or HSIL, with an ASC-US or worse smear (ASC-US+) and 1444 women with
normal screening cytology comprised the study cohorts. The positivity rate for the 3-type
HPV mRNA was 1.9% (28/1444). Rescreening revealed 23 women with ASC-US, two
women with LSIL, two women with ASC-H, and one woman with AGUS. If the HPV mRNA-
positivity rate and histology findings from samples rescreened were applied to all women
with normal cytology, an estimated increase in screening sensitivity of 16.4% (95% CI:15.3–
17.5) for CIN2+ and 17.3% (95% CI:16.2–18.4) for CIN3+ were achieved. By rescreening
less than 2% of women with normal cytology positive for a 3-type HPV mRNA test, we
achieved a significant increase in screening program sensitivity.
Introduction
Cytology screening for cervical cancer has been effective in reducing cervical cancer incidence
in countries with high-coverage and high-quality screening programs [1–4]. In the Nordic







Citation: Westre B, Giske A, Guttormsen H,
Wergeland Sørbye S, Skjeldestad FE (2019) Quality
control of cervical cytology using a 3-type HPV
mRNA test increases screening program sensitivity
of cervical intraepithelial neoplasia grade 2+ in
young Norwegian women—A cohort study. PLoS
ONE 14(11): e0221546. https://doi.org/10.1371/
journal.pone.0221546
Editor: Luca Giannella, Azienda Ospedaliero
Universitaria Ospedali Riuniti di Ancona Umberto I
G M Lancisi G Salesi, ITALY
Received: February 19, 2019
Accepted: August 11, 2019
Published: November 5, 2019
Copyright: © 2019 Westre et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
available from the Uit Open Research Data archive
at https://doi.org/10.18710/TDJV8X.
Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.
countries, this applies to slow growing cancers among women above 40 years of age, but not to
women younger than 40 years [3,5,6].
Primary HPV-screening with DNA-based tests find high-grade cervical intraepithelial neo-
plasia grade 2 and 3 (CIN2+) at an earlier time point than cytology based screening do [7].
However, over two screening rounds there were no difference in detection rates of CIN2+ [8].
A meta-analysis of randomized screening trials against cervical cancer reported more invasive
cervical cancer cases detected in the cytology-arm compared with the HPV-arm [9]. In women
younger than 30 years primary HPV DNA based screening is very ineffective and not cost-
effective due to the high prevalence of transient HPV-infections [10–12].
Worldwide HPV 16 and 18 are the most prevalent oncogenic types detected from cervical
cancer tissue [13–15]. Cancers associated with HPV-16/-18/-45 are more often diagnosed at
younger ages, supporting the hypothesis of faster progression to cancer than precancerous
lesions associated with other HPV types [16]. These three types may account for 98% of all
HPV-positive cervical adenocarcinomas diagnosed in younger women [16–18].
In Norway, there has been 30% increase in cervical cancer in women younger than 40 years
over the past 10 years [19]. About half of Norwegian women diagnosed with cervical cancer
have attended screening, of whom more than 57% had “normal” cytology at the most recent
smear less than 4 years before the cancer diagnosis. For the years 2007 through 2016, this com-
prised 344 women less than 40 years with a delayed diagnosis of cervical cancer (Table 1).
Rescreening of “normal” smears in women with cervical cancer often reveal abnormal cells
overlooked or misinterpreted in previous screening rounds [20,21].
In the present study, we assess the impact of quality control by co-testing cytology normal
young women with an HPV mRNA test targeting HPV-16/-18/-45 on screening program sen-
sitivity, and evaluate the subsequent workload for the screeners caused by re-screening smears
from women who had a positive mRNA test.
Material and methods
The Department of Pathology, Ålesund Hospital, assesses approximately 12 000 cervical
smears annually. The department uses the Bethesda system for classification of cervical
cytology and the WHO histological classification of tumors in cervical biopsies
Table 1. Number of cervical cancers among women< 70,< 25, and< 40 yrs., number of women< 40 yrs. with smears within 4 years of cancer diagnosis, and pro-
portion (%) of women with normal last smear before start of cascade of smears leading to a cancer diagnosis, Norway, 2007 through 2016 and total.
Year No. of cervical
cancers < 70 yrs.
No. of cervical
cancers < 25 yrs.
No. of cervical
cancers 25–39 yrs.
No. of women < 40 yrs. with
smears < 4 yrs. of cancer diagnosis
% women < 40 yrs. with normal last
smear before diagnosis of cancer
2007 206 2 64 43 48.8
2008 243 5 93 65 55.4
2009 260 6 94 62 46.7
2010 278 4 106 67 65.7
2011 259 5 107 66 51.5
2012 278 1 100 56 48.2
2013 243 6 74 40 55.0
2014 306 6 133 75 56.0
2015 338 5 126 67 58.0
2016 301 13 108 62 53.2
Total 2 712 53 1 005 603 57.0
Data sources: Annual reports The NCCSP 2008 through 2017, Institute of Population based Cancer Research. Oslo. Norway (in Norwegian).
https://doi.org/10.1371/journal.pone.0221546.t001
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(http://screening.iarc.fr/colpochap.php?chap=2). One experienced pathologist (BW) reviewed
all biopsies. Biopsies with uncertain cellular changes were immunostained with p16 (INK4a)
(Roche mtm laboratories AG). If there was a discrepancy between biopsy and treatment histol-
ogy, the most severe histology determined the endpoint.
HPV mRNA were detected using PreTect SEE (PreTect AS, Klokkarstua, Norway) a diag-
nostic kit for the qualitative detection and direct typing of E6/E7 mRNA from HPV 16, 18 and
45 according manufacturer’s instructions. The kit contains an intrinsic sample control (ISC)
targeting a human housekeeping gene to assess specimen quality and reveal possible factors
that may inhibit amplification. PreTect SEE sequences correspond to a subset of genotypes in
PreTect HPV-Proofer (PreTect AS) and make use of real-time NASBA technology, an enzy-
matic one-step amplification process able to amplify RNA under isothermal conditions
(41˚C).
Following national guidelines in delayed triage, Ålesund Hospital utilized the HPV DNA
test Cobas 4800 (Roche Molecular Diagnostics), which detects 14 HPV types. In addition,
HPV mRNA was detected using PreTect HPV-Proofer (PreTect AS, Norway), which detects
E6/E7 mRNA from types-16, -18, -31, -33, -45.
During the study period, the Norwegian Cervical Cancer Screening Programme (NCCSP)
recommended delayed triage of women with minor cervical lesions with repeat cytology and
HPV testing 6–12 months after the index diagnosis of atypical cells of undetermined signifi-
cance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL). In order to increase
sample size (power) without compromising validity of testing, and to mimic the real life of fol-
low-up in the NCCSP, we expanded the triage follow-up window from 90 to 540 days after the
index smear.
Referred to colposcopy/biopsy were women with high-grade squamous intraepithelial
lesions (HSIL) or repeated ASC-US/LSIL with a positive HPV test. Women with a normal
smear and a positive HPV test were recommended a repeat HPV test within 12 months,
whereas women with an ASC-US/LSIL/normal smear with a negative HPV test returned to
regular screening at a three-year interval [22].
We sampled cells for conventional cytology (Pap smear) with a wooden spatula and a brush
from the cervix uteri, and placed the material directly onto a glass slide followed by fixation.
The same brush was rinsed in ThinPrep (Cytec Corporation, Marlborough, USA), and sent for
subsequent HPV mRNA testing. In Norway, many hospitals have switched from conventional
Pap smears to liquid-based cytology (LBC), but Ålesund Hospital still used conventional Pap
smears over the study years.
From April 4th, 2013, the department started rescreening all normal smears among women
aged 23–39 years with a concurrent positive HPV mRNA test. During the inclusion-window
4747 women, 23 through 39 years of age had a valid smear. After exclusion of women with a
history of CIN1+ (n = 339) or HSIL without CIN (n = 42), the study population comprised
4366 women. During primary screening we defined four follow-up cohorts; a passive arm of
normal smears not tested for HPV (control arm), normal smears testing positive with the
3-type mRNA test (mRNA positive arm), follow-up of ASC_US-LSIL as the ASC_US-LSIL
arm, and the HSIL-arm as follow-up of women with HSIL. Follow-up continued for one
screening interval through December 31, 2017.
All analyses were done in SPSS, version 24.0, as differences between means (detection rates)
at significance level p< 0.05.
The Regional Committee for Medical and Health Research Ethics (REC Central) has
approved the protocol as a quality assurance study in laboratory work (2014/669/REK midt).
Norwegian regulations exempt quality assurance studies from written informed consent from
the patients.
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Results
In this low risk population of women younger than 40 years index smear were normal in
88.1% (3845/4366) of the women, 8.5% (370/4366) had ASC-US, 1.9% (82/4366) had LSIL
(ASC-US/LSIL-arm), and 1.6% (69/3466) had HSIL, ASC-H, AGUS or ACIS (HSIL-arm). In
samples diagnosed as normal, 1444 of 3851 (37.5%) had liquid based cytology (LBC) available
for HPV-testing. In this subset of women, the positivity rate for HPV mRNA was 1.9% (28/
1444) (mRNA-positive arm). Rescreening samples revealed 23 women with ASC-US, two
women with LSIL, two women with ASC-H and one woman with AGUS. Finally, the control
arm comprised 2401 women not tested for mRNA HPV (3845–1444).
At triage, eight of 28 women in the mRNA-positive arm and 199 out 452 women in the
ASC-US/LSIL arm returned to screening after having a negative HPV DNA test result and a
normal, ASC-US, or LSIL cytology reading. In the ASC-US/LSIL arm, 35 women had no cytol-
ogy follow-up, whereas 18 women had incomplete cytology follow-up. In the HSIL arm, two
women never met for biopsy, and two women had only cytology follow-up. In total 20 women
in the mRNA positive arm, 139 women in the ASCUS-LSIL arm, and 65 women in the HSIL
arm had biopsies collected (Table 2).
Among women in the mRNA-positive arm, 32.2% (9/28) were CIN2+, respective 18.8%
(85/452) in the ASC-US/LSIL-arm, and 88.4% (61/69) in the HSIL-arm. In total 146 women
were diagnosed with CIN2+ in the ASC-US/LSIL- and HSIL-arms as practiced in the routine
screening program (Table 2).
The overall screening program detection rate were 3.3% (95% CI: 2.8%-3.9%) for CIN2+,
respective 2.8 (95% CI: 2.3%-3.3%) for CIN3+ (Table 3). By rescreening 28 samples (1.9%)
HPV-mRNA positive of the 1 444 normal samples, and applying these findings to women with
normal smear, not mRNA-tested, the overall program detection rate increased to 3.9% and
3.3% for CIN2+ and CIN3+ (Table 3), which constituted an estimated increase in screening
program sensitivity of 16.4% (95% CI: 15.3–17.5) for CIN2+ and 17.3% (95% CI: 16.2–18.4)
for CIN3+, respectively.
During follow-up we diagnosed 23 cases of CIN2+ among 1 700 out 2 401women with nor-
mal smear and no mRNA testing at baseline. In this subset of women 19 CIN2/3 cases were
tested at time for biopsy with a mRNA- or a DNA-test, among which 15 cases were positive for
HPV-16, -18 or -45 in one (n = 8) or both tests (n = 7). Only one case was HPV-negative in
both tests, while two cases were positive for HPV-31, and one case for HPV-33. There was







N = 28 N = 452 N = 69
No follow-up 0 35 2
Back to screening at triage 8 199
Incomplete follow-up 0 79 2
Histology
Normal 5 24 2
CIN 1 6 30 2
CIN 2 1 17 6
CIN 3 8 66 53
Squamous cell ca. 0 2 1
Adenocarcinoma 0 0 1
https://doi.org/10.1371/journal.pone.0221546.t002
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100% concordance between the mRNA- and the DNA-test results among the seven cases
tested by both tests.
Norway has started, and will within 2021, implement national screening for cervical cancer
with a primary DNA test for women 34 through 69 years of age, and continue cytology based
screening for women 25 through 33 years. By restricting the analyses to women aged 23 to 33
years, the study population comprised 2770 women, with a HPV mRNA-positivity rate of
2.6%. The estimated increase in screening sensitivity for CIN2+ and CIN3+ in this subset of
women were 21.3% (95% CI: 20.1–22.5) and 14.1% ((95% CI:13.1–15.1), respectively.
We diagnosed four cases of cervical cancer during follow-up after a positive screening cytol-
ogy outcome (2 after ASCUS, 1 after HSIL and 1 after ASC-H) (Table 3). For three of these
women index smear was first smear ever. Two women were diagnosed at age 23 and 24 before
screening starts, and in one women at age 37when attending screening for the first time ever.
All four cases were HPV positive (3 HPV-16, 1 HPV-31) and diagnosed in early stage 1A1.
Discussion
By rescreening less than 2% of cytological normal samples that were positive for HPV E6/E7
mRNA types 16, 18 and 45, we achieved a significant increase in program detection rate for
CIN3+ of 17–18%. Cervical cytology has a high rate of false negative samples. Low sensitivity
for cytology in detection of CIN3 or invasive cervical cancer has been an issue for decades
[23]. Case-series of women diagnosed with cervical cancer have revealed that younger women
to a larger extend have a diagnosis of false negative smears during screening, while older
women are under-screened or not participating in organized screening programs [21,24–26].
An improvement in diagnostic accuracy in cytology is one element of quality assessment in
cervical cancer screening programs. While cytology represents morphological cellular changes,
the detection of HPV mRNA expresses oncogenic molecular activity. Traditionally rescreening
of a proportion of slides are considered an acceptable method for quality assessment if concor-
dance of readings are high. However, this method is time consuming and tedious for cyto-
technicians, and human errors are easily repeated (10). A molecular method is complementary
to cytology in validation of diagnostic accuracy. It is therefore important that the molecular
method target the HPV types that comprise the highest risk for progression to cervical cancer.
One way of expressing progression rate of precancerous lesions to cervical cancer is to
study prevalence ratio of HPV types found in cancer tissue by types in tissue from CIN3. A
ratio above 1.0 expresses an association, while an expression less than 1.0 weakens the potential
oncogenic properties of the targeted HPV types. Worldwide, publications consistently report
HPV 16, 18 and 45 with a prevalence ratio above 1.0, while most other HPV-types have preva-
lence ratios less than 0.4 [16,18,27]. The PreTect SEE test comprises the three HPV-types that
Table 3. Detection rates for CIN2+ and CIN3+ by status screening and estimated no. of CIN2+/CIN3+ cases among women with normal index cytology and no
HPV-testing.
Outcome Control arm�- normal smears–
not mRNA tested




N = 2 401 N = 1 444 N = 452 N = 69 N = 4 366
CIN 2+ As practiced 85 61 146 3.3 (2.8–3.9)
+ rescreening 15� 9 85 61 170 3.9 (3.3–4.5)
CIN 3+ As practiced 52 55 123 2.8 (2.3–3.3)
+ rescreening 13.3� 8 52 55 144.3 3.3 (2.8–3.8)
�Estimated no. of cases based on detection rate in the mRNA-positive arm.
https://doi.org/10.1371/journal.pone.0221546.t003
Screening sensitivity increases significantly after rescreening normal smears with a mRNA HPV test
PLOS ONE | https://doi.org/10.1371/journal.pone.0221546 November 5, 2019 5 / 9
are most important for progression of precancerous lesions into cancer among younger
women, and detects oncogenic activity in false negative cytology samples.
Transient infections of many HPV-types are prevalent in the female genital tract. Most
women have normal smear readings from cervix uteri in situations of transient infections
[28,29]. In order to increase accuracy of cytology as method in cervical screening, it is impor-
tant that a complementary HPV validation-test target oncogenic activity among major HPV-
types in the etiology of cervical cancer. An HPV-DNA-test covering many types will detect too
many transient infections leading to a higher rescreening rate, followed by more referrals to
colposcopy in situations of HPV-infections with low potential of progression of the normal
cell to CIN2/3 [30], and little potential, if any at all, of progression into cancer. This is crucial
in surveillance of younger women where the majority of CIN2 cases regress to normal cells
within few years [31–33].
The strength of our study is the population-based study design in a country having had a
well-organized screening program for over 20 years. We excluded women with a history of
high-grade cytology and/or CIN1+ that would represent persistent HPV infections, thus leav-
ing a subset of low-risk women being exposed or not exposed to a probable incident HPV
infection with oncogenic expression.
Our study reflects the “real life” situation, the way women participate in the screening pro-
gram, and how women and their doctors adhere to the recommended follow-up algorithms.
We tried to avoid observation and attrition bias by comparing follow-up outcomes within one
screening interval. The follow-up of women with normal cytology and no mRNA testing
(N = 1701) revealed 23 incident cases of CIN2/3, among which 15 out of 19 tested positive for
HPV 16, 18 and 45. This indicates that the estimates for increase in screening sensitivity by
rescreening all women with normal cytology with a positive HPV mRNA test may be an
underestimate of what is possible to achieve in a real life among women less than 40 years.
According to annual reports from the NCCSP 1058 of 2712 (39%) cervical cancers were
diagnosed among women less than 40 years in Norway over the 10-year period 2007 through
2016 (Table 1). Among women less than 40 years of age, 603 women had at least one valid
smear prior start of examinations leading to a cancer diagnoses. In this subset, 344 (57%)
women had a false normal smear at the most recent visit within 4 years of cancer. Norway will
continue with cytology based screening in women aged 25 through 33 years after implementa-
tion of primary HPV DNA-based screening. As most cervical cancers develop over decades,
and in order to diagnose the more aggressive HPV-types, it will be important to validate nor-
mal smears with a molecular method in the younger age groups, at a time point where the
lesions have not penetrated the basal membrane of the cervix uteri. It was in this subset of
women we increased the detection rate by 14–15% for CIN3 when applying a mRNA test as
validation of presumptive normal smears. Our sample size is not large enough for discovering
any cases of cervical cancer in the group of women having a normal smear and no mRNA test-
ing at baseline, but large enough for a valid confirmation of estimated versus observed cases of
CIN3.
In 2011 the costs of the NCCSP were NOK 730 millions when approximately 3500 CIN2+
were diagnosed [34]. If we assume that the costs for the NCCSP has remained at this level for
the most recent years an average cost for a CIN2+ in NCCSP (n = 6000) [35] were NOK 120
000 (USD 15000) in 2016. If we apply the results from the present study to rescreening of the
100 000 women with normal screens aged 23–39 years in Norway (mRNA test = NOK 250 all
costs included), rescreening rate of 2% (a cytology examination reimbursed with NOK 70),
more than 540 (95% CI: 500–590) new cases of CIN2+ may be detected. An average cost for an
additional case of CIN2+ with rescreening of assumed normal smears will be NOK 46666
(95% CI: NOK 42610–50280). The women rescreened are in the system, and they do not need
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reminders if no show-up in subsequent screening rounds. Rescreening of normal smears with
a mRNA test may be cost-effective in case-finding of CIN2+. However, these results have to be
confirmed in more detailed cost-effectiveness analyses of rescreening presumable normal
smears with a 3-type mRNA test from results in prospective ongoing studies.
In order to prevent cervical cancer with screening in women less than 40 years, high quality
diagnosis and treatment of precancerous lesions before age 34 will be important for many
years. In Norway, we have to wait until 2037 before the fully vaccinated cohorts reach 40 years.
Conclusions
By testing all women less than 40 years of age with normal cytology with a specific 3-type HPV
mRNA test, we achieved a significant (17–18%) increase in screening program sensitivity for
CIN3. The 3-type HPV mRNA is a high throughput assay, representing similar workload as
any HPV DNA test commonly used in primary screening. The volume of rescreened smears
(1.9%) represent a low workload. In addition, the study adds quality to educating the screeners
by rescreening presumably false negative Pap-smears.
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